ConductScience.org, home

Paper41333210

Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response.

Wang H and 4 others. Front Oncol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response. Papers, record 41333210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41333210

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response.
PubMed
Journal
Front Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-05
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang HHaoqi
2Gao SShan
3Bai ZZihao
4Wang LLijia
5Geng CCuizhi

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139184927Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.Transl Breast Cancer Res2024https://conductscience.org/library/papers/39184927PubMed
233446565Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy.Clin Cancer Res2021https://conductscience.org/library/papers/33446565PubMed
334016991HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.NPJ Breast Cancer2021https://conductscience.org/library/papers/34016991PubMed
428081544Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.Br J Cancer2017https://conductscience.org/library/papers/28081544PubMed
538273267Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.BMC Cancer2024https://conductscience.org/library/papers/38273267PubMed
636494872Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study.Cancer Imaging2022https://conductscience.org/library/papers/36494872PubMed
732652460Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer.Breast2020https://conductscience.org/library/papers/32652460PubMed
824529560Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet2014https://conductscience.org/library/papers/24529560PubMed
928938652Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis.Oncotarget2017https://conductscience.org/library/papers/28938652PubMed
1031267973Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.Lancet Oncol2019https://conductscience.org/library/papers/31267973PubMed
1136575513Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.BMC Med2022https://conductscience.org/library/papers/36575513PubMed
1230179110Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.Radiology2018https://conductscience.org/library/papers/30179110PubMed
1335235873
Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Eur J Cancer2022https://conductscience.org/library/papers/35235873PubMed
1428115222Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.Eur J Pharm Sci2017https://conductscience.org/library/papers/28115222PubMed
1525580585Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.J Magn Reson Imaging2015https://conductscience.org/library/papers/25580585PubMed
1632227407Role of MRI to Assess Response to Neoadjuvant Therapy for Breast Cancer.J Magn Reson Imaging2020https://conductscience.org/library/papers/32227407PubMed
1729045232Imaging Neoadjuvant Therapy Response in Breast Cancer.Radiology2017https://conductscience.org/library/papers/29045232PubMed
1831705004Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response - A Prospective Study.Sci Rep2019https://conductscience.org/library/papers/31705004PubMed
1938114991Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.World J Surg Oncol2023https://conductscience.org/library/papers/38114991PubMed
2025891905Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.Clin Breast Cancer2015https://conductscience.org/library/papers/25891905PubMed

See all 55 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41333210

GET https://conductscience.org/api/papers/v1/41333210/references?page=2